The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 

The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment, this money enables scientists to produce top-quality research which will in turn result in discoveries and drugs that help tackle disease and areas of unmet need. Here are five financial success stories that made headlines this week.

You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.   

In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.

Dr Worland has significant experience as a scientist and C-suite level executive/entrepreneur, and today speaks about how Selective Translation Regulator Inhibitors (STRIs) are unique to other cancer treatments, the future of the industry as well as the significance of pharma collaboration in the development process.

You can find the Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 

The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery. These include the detection of new targets for skin cancer treatment, the benefits of vitamin D for cancer prevention, an extended approval in the EU for a CAR-T myeloma therapy and the discovery of an unusual source of targeted treatments.

This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW.

They are called: Going paperless – the move to electronic lab notebooks, New horizon for cancer innovation, and A personal touch: the role of bioprinting in drug discovery.

In the first article, Barry Bunin, PhD, CEO of Collaborative Drug Discovery explores the rise of electronic lab notebooks and why researchers should be transitioning to digital methods of recording data.

In the second article, Reece Armstrong sits down with Cancer Research Horizons’ Chief Business Officer, Tony Hickson and CEO of its Therapeutics division, Hamish Ryder, to learn about the organisation’s goals.

In the third article, DDW Editor, Reece Armstrong, sits down with Brinter CEO Tomi Kalpio to learn about the company’s approach to bioprinting and how it can be used throughout drug discovery.

You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 

The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s.

You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 

The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so this round-up focuses on drug discovery in oncology.

You can to The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 

In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders and alcohol use disorder, and a significant acquisition for Novo Nordisk, as well as the discovery of a new way to target dormant cancer cells.

You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Flow cytometry for drug discovery research” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW.

They are called: Flow cytometry technologies and cancer associated fibroblasts and Leveraging flow cytometry in drug discovery.

In the first article, Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done.

In the second article, Dr Miguel A Tam, and Dr Kenta Yamamoto, BioLegend, examine the evolution, trends and best practices for smooth and efficient workflows for flow cytometry.

You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 

Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease.

You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.   

In this episode, Megan Thomas is in conversation with Ahmed Mousa, CEO of Vicore Pharma. Vicore Pharma is exploring the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), and here Mousa provides DDW with an overview of the company’s unique approach, its challenges, its opportunities, and its context in the scientific community. 

You can listen here, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 

It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and the announcement that the FDA will delay approval of donanemab to hold a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee.

You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.